The role of the locus coeruleus in the development of Parkinson's disease

Neuroscience and Biobehavioral Reviews

Volumn 24, Issue 6, 2000, Pages 655-668

  Gesi, M ^a   Soldani, P ^a   Giorgi, F S ^a   Santinami, A ^a   Bonaccorsi, I ^b   Fornai, F ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; DSP 4; Experimental parkinsonism; Locus coeruleus; Methamphetamine; Norepinephrine; Parkinson's disease

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE; NORADRENALIN;

CELL DEATH; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; HUMAN; IMMEDIATE EARLY GENE; LOCUS CERULEUS; NEUROPATHOLOGY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SUBSTANTIA NIGRA;

EID: 0033884355     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(00)00028-2     Document Type: Article

References (141)

1. Falck H., Hillarp N.A., Thieme G., Torp A. Fluorescence of catecholamines and related compounds condensed with formaldehyde. J Histochem Cytochem. 10:1962;348-354.
2. Gaspar P. Anatomy of the noradrenergic pathways in the primate brain: alteration in Parkinson's disease. Marien M., Briley M. Noradrenergic mechanisms in Parkinson's disease. 1994;74-88 CRC Press, Boca Raton.
3. Brodal A. Neurological anatomy in relation to clinical medicine. 1981;Oxford University Press, New York. (p. 416-419).
4. Russell G.V. The nucleus locus coeruleus (dorsolateralis tegmenti). Tex Rep Biol Med. 13:1955;939-988.
5. Nieuwenhuys J.V., Voogd J., VanHuijzen C. The human central nervous system: a synopsis and atlas. 1988;Springer, Berlin.
6. Mann D.M. The Locus Coeruleus and its possible role in ageing and degenerative disease of the human central nervous system. Mech Ageing and Develop. 23:1983;73-94.
7. Amaral D.G., Sinnamon H.M. The locus coeruleus: neurobiology of a central noradrenergic nucleus. Prog Neurobiol. 9:1977;147-196.
8. Foote S.L., Bloom F.E., Aston-Jones G. Nucleus locus coeruleus: new evidence of anatomical and physiological specificity. Physiol Rev. 63:1983;844-914.
9. Jouvet M. The role of monoamines and acetylcholine containing neurons in the regulation of the sleep-waking cycle. Rev Physiol Biochem Exp Pharmacol. 64:1972;166-307.
10. Aston-Jones G., Bloom F.E. Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J Neurosci. 1:1981;876-886.
11. Aston-Jones G., Chiang C., Alexinski T. Discharge of noradrenergic locus coeruleus neurons in behaving rats and monkeys suggests a role in vigilance. Barnes C.D., Pompeiano O. Progress in brain research. vol. 88:1991;501-520 Elsevier, Amsterdam.
12. Arnsten A., Goldman-Rakic P.S. Selective prefrontal cortical projections to the region of the locus coeruleus and raphè nuclei in the rhesus monkey. Brain Res. 306:1984;9-18.
13. Aston-Jones G., Rajkowski J., Kubiak P., Alexinski T. Locus Coeruleus neurons in monkey are selectively activated by attended cues in a vigilance task. J Neurosci. 14:1994;4467-4480.
14. Vankov A., Hervè-Minvielle A., Sara S.J. Response to novelty and its rapid habituation in locus coeruleus neurons of the freely exploring rat. Eur JNeurosci. 7:1995;1180-1187.
15. Foote S.L., Berridge C.W., Adams L.M., Pineda J.A. Electrophysiological evidence for the involvement of the locus coeruleus in alerting, orienting, and attending. Barnes C.D., Pompeiano O. Progress in brain research. vol. 88:1991;521-532 Elsevier, Amsterdam.
16. Ward D.G., Gunn C.G. Locus coeruleus complex: elicitation of a pressor response and a brainstem region necessary for its occurrence. Brain Res. 107:1976;401-406.
17. Gubits R.M., Smith T.M., Fairhurst J.L., Yu H. Adrenergic receptors mediate changes in c-fos mRNA levels in brain. Mol Brain Res. 6:1989;39-45.
18. Bing G., Filer D., Miller J.C., Stone E.A. Noradrenergic activation of immediate early genes in rat cerebral cortex. Mol Brain Res. 11:1991;43-46.
19. Stone E.A., Zhang Y., John S., Filer D., Bing G. Effect of locus coeruleus lesion on c-fos expression in the cerebral cortex caused by yohimbine injection or stress. Brain Res. 603:1993;181-185.
20. Cirelli C., Pompeiano M., Tononi G. Neuronal gene expression in the waking state: a role for the locus coeruleus. Science. 274:1996;1212-1215.
21. Aghajanian G.K., Van der Maelen C. Alpha-2 adrenoceptor mediated hyperpolarization of locus coeruleus neurons: intracellular studies in vivo. Science. 215:1982;1394-1396.
22. Shen P.J., Burazin T.C.D., Gundlach A.L. Noradrenergic regulation of immediate early gene expression in rat forebrain: differential effects of alpha1- and alpha2-adrenoceptor drugs. Mol Brain Res. 28:1995;222-230.
23. Forno L.S. Neuropathology of Parkinson's Disease. J Neuropathol Exp Neurol. 55:1996;259-272.
24. Arima K., Akashi T. Involvement of the locus coeruleus in Pick's disease with or without Pick body formation. Acta Neuropathol. 79:1990;629-633.
25. Baker K.G., Törk I., Hornung J.P., Halasz P. The human locus coeruleus complex: an immunohistochemical and three-dimensional reconstruction study. Exp Brain Res. 77:1989;257-270.
26. Chan-Palay V., Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer's type and in Parkinson's disease with and without dementia and depression. J Comp Neurol. 287:1989;373-392.
27. Greenfield J.G., Bosanquet F.D. The brain-stem lesions in Parkinsonism. J Neurol Neurosurg Psychiatry. 16:1953;213-226.
28. Manaye K.F., Woodward K., Mc Intire D.D., Mann D.M.A., German D.C. Locus Coeruleus cell loss in lobar atrophy. Neurodegeneration. 3:1994;205-210.
29. Tretiakoff C. Contribution à l'étude de l'Anatomie pathologique du Locus Niger de Soemmering avec quelques déductions relatives à la pathogenie des troubles du tonus musculaire de la maladie de Parkinson. Thèse de Paris, 1919.
30. Ehringer H., Hornykiewicz O. Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen systems. Klin Wschr. 38:1960;1236-1239.
31. Mavridis M., Degryse A.D., Lategan A.J., Marien M.R., Colpaert F.C. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience. 41:1991;507-523.
32. Fornai F., Bassi L., Torracca M.T., Scalori V., Corsini G.U. Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice. Eur J Pharmacol. 283:1995;99-102.
33. Marien M., Briley M., Colpaert F. Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice. Eur J Pharmacol. 236:1993;487-489.
34. Kilbourn M.R., Sherman P., Abbott L.C. Reduced MPTP neurotoxicity in the striatum of the mutant mouse tottering. Synapse. 30:1998;205-210.
35. Fornai F., Alessandrì M.G., Torracca M.T., Bassi L., Scalori V., Corsini G.U. Noradrenergic modulation of methamphetamine-induced striatal dopamine depletion. Ann NY Acad Sci. 844:1998;166-177.
36. Gerlach M., Jellinger K., Riederer P. The possible role of noradrenergic deficits in selected signs of Parkinson's disease. Marien M., Briley M. Noradrenergic mechanisms in Parkinson's disease. 1994;59-71 Boca Raton, CRC Press.
37. Hornykiewicz O., Kish S.J. Biochemical pathophysiology of Parkinson's disease. Adv Neurol. 45:1986;19-34.
38. German D.C., Walker B.S., Manaye K., Smith W.K., Woodward D.J., North A.J. The human locus coeruleus: computer reconstruction of cellular distribution. J Neurosci. 8:1988;1776-1788.
39. Olszewski J., Baxter D. Cytoarchitecture of the human brain stem. 1954;Karger, New York.
40. Chan-Palay V., Asan E. Quantification of catecholamine neurons in the locus coeruleus in the human brain of normal young and older adults and in depression. J Comp Neurol. 287:1989;357-372.
41. Vijayashankar N., Brody H.A. Quantitative study of the pigmented neurons in the locus coeruleus and sub-coeruleus in man as related to ageing. J Neuropathol Exp Neurol. 38:1979;490-494.
42. Iversen L.L., Rossor M.N., Reynolds G.P., Hills R., Roth M., Mountjoy C.Q., Foote S.L., Morrison J.H., Bloom F.E. Loss of pigmented dopamine-beta-hydroxylase positive cells from locus coeruleus in senile dementia of Alzheimer's type. Neurosci Lett. 39:1983;95-100.
43. Choi B.H., Antanitus D.S., Lapham L.W. Fluorescence histochemical and ultrastructural studies of locus coeruleus of human fetal brain. J Neuropathol Exp Neurol. 34:1975;507-516.
44. Nobin A., Bjorklund A. Topography of the monoamine neuron systems in the human brain as revealed in fetuses. Acta Physiol Scand. 388:(Suppl):1973;1-40.
45. Nagai T., Satoh K., Immamoto K., Maeda T. Divergent projections of catecholamine neurons of the locus coeruleus as revealed by fluorescent retrograde double labeling technique. Neurosci Lett. 23:1981;117-123.
46. Room P., Postema F., Korf J. Divergent axon collaterals of rat locus coeruleus neurons: demonstration by a fluorescent double-labeling technique. Brain Res. 221:1981;219-230.
47. Harik S.I., McGunigal T. Jr. The protective influence of the locus coeruleus on the blood-brain barrier. Ann Neurol. 15:1984;568-574.
48. Stone E.A., Ariano M.A. Are glial cells targets of the central noradrenergic system? A review of the evidence. Brain Res Rev. 14:1989;297-309.
49. Levitt P., Moore R.Y. Origin and organization of brainstem catecholamine innervation in the rat. J Comp Neurol. 186:1979;505-528.
50. Fuxe K., Hökfelt T., Ungerstedt U. Morphological and functional aspects of central monoamine neurons. Pfeifer C.C., Smythies J.R. Int Rev Neurobiol. 13:1970;93-126 Academic Press, New York.
51. Maeda T., Shimizu N. Projections ascendantes du locus coeruleus et d'autres neurones aminergiques pontiques au niveau du prosencephale du rat. Brain Res. 36:1972;19-35.
52. Rinvik E., Grofova I., Hammond C., Deniau J.M., Feger J. Afferent connections to the subthalamic nucleus in the monkey and the cat studied with the HRP technique. Poirier L.J., Sourkes T.L., Bedard P.J. The extrapyramidal system and its disorders. 1979;53-70 Raven Press, New York.
53. Collingridge G.L., James T.A., MacLeod N.K. Neurochemical and electrophysiological evidence for a projection from the locus coeruleus to the substantia nigra. J Physiol. 290:1979;44.
54. Jones B.E., Moore R.Y. Ascending projections of the locus coeruleus in the rat. II Autoradiographic study. Brain Res. 127:1977;23-53.
55. Olson L., Fuxe K. On the projections from the locus coeruleus noradrenaline neurons: the cerebellar innervation. Brain Res. 28:1971;165-171.
56. Olson L., Fuxe K. Further mapping out of central noradrenaline neuron systems: projections of the subcoeruleus area. Brain Res. 43:1972;289-295.
57. Mizuno N., Nakamura Y. Direct hypothalamic projections to the locus coeruleus. Brain Res. 19:1970;160-162.
58. Snider R.S. A cerebellar-ceruleus pathway. Brain Res. 88:1975;59-63.
59. Sakai K., Touret M., Salvert D., Leger L., Jouvet M. Afferent projections to the cat locus coeruleus as visualized by the horseradish peroxidase tecnique. Brain Res. 119:1977;21-41.
60. Hopkins D.A., Holstege G. Amygdaloid projections to the mesencephalon, pons, medulla oblongata in the cat. Exp Brain Res. 32:1978;529-547.
61. Beckstead R.M., Domesick V.B., Nauta W.J.H. Efferent connections of the substantia nigra and ventral tegmental area in the rat. Brain Res. 175:1979;191-217.
62. Cedarbaum J.M., Aghajanian G.K. Afferent projections to the rat locus coeruleus as determined by a retrograde tracing technique. J Comp Neurol. 178:1978;1-16.
63. Alvord E.C. Jr., Forno L.S. Pathology. Koller W.C. Handbook of Parkinson's disease. 1987;209-236 Marcel Dekker, New York.
64. Beheim-Schwarzbach D. Uber zelleib-veranderungen im nucleus coeruleus bei Parkinson symptomen. J Nerv Ment Dis. 116:1952;619-632.
65. German D.C., Manaje K.F., White C.L., Woodward D.J., McIntire D.D., Smith W.K., Kalaria R.N., Mann D.M. Disease specific pattern of locus coeruleus cell loss. Ann Neurol. 32:1992;667-676.
66. Alvord E.C. Jr., Forno L.S. Koller W.C. Handbook of Parkinson's disease. 2nd ed :1992;258-259 Marcel Dekker, New York.
67. Bertrand E., Lechowicz W., Szpak G.M., Dynecki J. Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson's disease. Folia Neuropathol. 35:1997;80-86.
68. Forno L.S., Eng L.F., Selkoe D.J. Pick bodies in the locus coeruleus. Acta Neuropathol. 79:1989;10-17.
69. Paulus W., Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol. 50:1991;743-755.
70. Patt S., Gerhard L. A Golgi study of human locus coeruleus in normal brains and in Parkinson's disease. Neuropathol Appl Neurobiol. 19:1993;519-523.
71. Gaspar P., Duickaerts C., Alvarez C., Javoy-Agid F., Berger B. Alterations of dopaminergic and noradrenergic innervations in motor cortex of Parkinson's disease. Ann Neurol. 30:1991;365-374.
72. Berniheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndroms of Parkinson and Huntington. J Neurol Sci. 20:1973;415-455.
73. Hornykiewicz O., Pifl C. The validity of the MPTP primate model for neurochemical pathology of idiopathic Parkinson's disease. Briley M., Marien M. Noradrenergic mechanisms in Parkinson's disease. 1994;59-71 CRC Press, Boca Raton.
74. Riederer P., Birkmayer W., Seeman D., Wuketich S. Brain noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's disease. J Neural Transm. 41:1977;241-251.
75. Kish S.J., Shannak K.S., Rajput A.H., Gilbert J.J., Hornykiewicz O. Cerebellar norepinephrine in patients with Parkinson's disease and control subjects. Arch Neurol. 41:1984;612-614.
76. Scatton B., Dennis T., L'Hereux R., Monfort J., Duyckaerts C., Javoy-Agid F. Degeneration of noradrenergic and serotoninergic but not dopaminergic neurons in the lumbar spinal cord of parkinsonian patients. Brain Res. 380:1986;181-185.
77. Farley I.J., Hornykiewicz O. Noradrenaline in subcortical brain regions of patients with Parkinson's disease and control subjects. Birkmayer W., Hornykiewicz O. Advances in parkinsonism. 1976;178-185 Editiones Roche, Basel.
78. Scatton B., Javoy-Agid F., Roquier L., Dubois B., Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. 275:1983;321-328.
79. Ungerstedt U. 6-hydroxydopamine induced degeneration of central monoamine neurons. Eur J Pharmacol. 5:1968;107-110.
80. Uretsky N.J., Iversen L.L. Effects of 6-hydroxydopamine on catecholamine containing neurones in the brain. Nature. 221:1969;557.
81. Burns R.A., Chieuh C.C., Markey S.P., Elbert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA. 80:1983;4546-4550.
82. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
83. Seiden L.S., Fischman M.W., Schuster C.R. Long-term methamphetamine induced changes in brain catecholamine in tolerant rhesus monkeys. Drug Alcohol Depend. 1:1975;215-219.
84. Seiden L.S., Ricaurte G.A. Neurotoxicity of methamphetamine and related drugs. Meltzer H.Y. Psychopharmacology: the third generation of progress. 1987;359-366 Raven Press, New York.
85. Forno L.S., Langston J.W., DeLanney L.E., Irwin I., Ricaurte G.A. Locus coeruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol. 20:1986;449-455.
86. Seniuk N.A., Tatton W.G., Greenwood C.E. Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res. 27:1990;7-20.
87. Pifl C.H., Schingnitz G., Hornykiewicz O. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of the monoamines in rhesus monkeys. Neuroscience. 44:1991;591-605.
88. Bing G., Zhang Y., Watanabe Y., McEwen B.S., Stone E.A. Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res. 668:1994;261-265.
89. Reading P.J., Dunnett S.B. 6-Hydroxydopamine lesions of nigrostriatal neurons as an animal model of Parkinson's disease. Woodruff M.L., Nonneman A.J. Toxins-induced models of neurological disorders. 1994;89-119 Plenum Press, New York.
90. Lidbrink P., Jonsson G. Noradrenaline nerve terminals in the cerebral cortex: effects on noradrenaline uptake and storage following axonal lesion with 6-hydroxydopamine. J Neurochem. 22:1974;617-626.
91. Cooper B.R., Breese G.R., Grant L.D., Howard J.L. Effects of 6-hydroxydopamine treatments on active avoidance responding: evidence for involvement of brain dopamine. J Pharmacol Exp Ther. 185:1973;358-370.
92. Luthman J., Fredriksson A., Sundstrom E., Jonsson G., Archer T. Selective lesion of central dopamine or noradrenaline neuron system in the neonatal rat: motor behaviour and monoamine alterations at adult stage. Behav Brain Res. 33:1989;267-277.
93. Ross S.B. Long-term effects of N-2-chloroethyl-N-ethyl-2-bromobenzylamine hydrochloride on noradrenergic neurones in the rat brain and heart. Br J Pharmacol. 58:1976;521-527.
94. Ross S.B., Renyi A.L. On the long-lasting inhibitory effect of N-(-2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) on the active uptake of noradrenaline. J Pharm Pharmacol. 28:1976;458-459.
95. Delini-Stula A., Mogilnicka E., Hunn C., Dooley D.J. Novelty-oriented behavior in the rat after selective damage of locus coeruleus projections by DSP-4, a new noradrenergic neurotoxin. Pharmacol Biochem Behav. 20:1984;613-618.
96. Dooley D.J., Bittiger H., Hauser K.L., Bischoff S.F., Waldmeier P.C. Alteration of central alpha2-adrenergic receptors in the rat after DSP-4, a selective noradrenergic neurotoxin. Neuroscience. 9:1983;889-898.
97. Jaim-Etcheverry G., Zieher L.M. DSP-4: a novel compound with neurotoxic effects on noradrenergic neurons of adult and developing rats. Brain Res. 188:1980;513-523.
98. Jonsson G., Hallman H., Ponzio F., Ross S. DSP-4 (N-(-2-chloroethyl)-N-ethyl-2-bromobenzylamine) - a useful denervation tool for central and peripheral noradrenaline neurons. Eur J Pharmacol. 72:1981;173-188.
99. Fritschy J.M., Grzanna R. Immunohistochemical analysis of the neurotoxic effects of DSP-4 identifies two populations of noradrenergic axon terminals. Neuroscience. 30:1989;181-197.
100. Fritschy J.M., Grzanna R. Restoration of ascending noradrenergic projections by residual locus coeruleus neurons: compensatory response to neurotoxin-induced cell death in the adult rat brain. J Comp Neurol. 321:1992;421-441.
101. Hallman H., Jonsson G. Pharmacological modifications of the neurotoxic action of the noradrenaline neurotoxin DSP-4 on central noradrenaline neurons. Eur J Pharmacol. 103:1984;269-278.
102. Zieher L.M., Jaim-Etcheverry G. Neurotoxicity of N-2′-chloroethyl-N-ethyl-2-bromobenzylamine hydrochloride (DSP-4) on noradrenergic neurons is mimicked by its cyclic aziridinium derivative. Eur J Pharmacol. 65:1980;249-256.
103. Wagner G.C., Ricaurte G.A., Eiden L.S., Schuster C.R., Miler R.J., Wetley J. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res. 181:1980;151-160.
104. Sonsalla P.K., Giovanni A., Sieber B.A., Delle Donne K., Manzino L. Characteristics of dopaminergic neurotoxicity produced by MPTP and methamphetamine. Ann NY Acad Sci. 648:1992;229-238.
105. Fornai F., Torracca M.T., Bassi L., D'Errigo D.A., Scalori V., Corsini G.U. Norepinephrine loss selectively enhances chronic nigrostriatal dopamine depletion in mice and rats. Brain Res. 735:1996;349-353.
106. Giovanni A., Sieber B.A., Heikkila R.E., Sonsalla P.K. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part I: sistemic administration J Pharmacol Exp Ther. 270:1994;1000-1007.
107. Giovanni A., Sonsalla P.K., Heikkila R.E. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part II: central administration of 1-methyl-4-phenylpyridinium. J Pharmacol Exp Ther. 270:1994;1008-1014.
108. Poewe W.H., Wenning G.K. The natural history of Parkinson's disease. Ann Neurol. 44:1998;S1-S9.
109. Otto D., Unsicker K. Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice. J Neurosci. 10:1990;1912-1921.
110. Fornai F., Alessandrì M.G., Torracca M.T., Bassi L., Corsini G.U. Effects of noradrenergic lesions on MPTP/MPP+kinetics and MPTP-induced nigrostriatal dopamine depletions. J Pharmacol Exp Ther. 283:1997;100-107.
111. Fornai F., Giorgi F.S., Alessandrì M.G., Giusiani M., Corsini G.U. Effects of pretreatment with DSP-4 on methamphetamine-induced striatal dopamine losses and pharmacokinetics. J Neurochem. 72:1999;777-784.
112. Zuddas A., Corsini G.U., Schinelli S., Johannessen J.N., di Porzio U., Kopin I.J. MPTP treatment combined with ethanol or acetaldehyde selectively destroys dopaminergic neurons in mouse sustantia nigra. Brain Res. 501:1989;1-10.
113. Nishi K., Kondo T., Narabayashi H. A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism: effect of norepinephrine terminal destruction. No To Shinkei. 39:1987;663-672.
114. Fornai F., Bassi L., Torracca M.T., Alessandrì M.G., Scalori V., Corsini G.U. Region- and neurotransmitter-dependent species and strain differences in DSP-4-induced monoamine depletion in rodents. Neurodegeneration. 5:1996;241-249.
115. Melamed E., Pikarski E., Goldberg A., Rosenthal J., Uzzan A., Conforti N. Effect of serotonergic, corticostriatal and kainic acid lesions on the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice. Brain Res. 399:1986;178-180.
116. Herkenham M., Little M.D., Bankiewicz K., Yang S.C., Markey S.P., Johannessen J.N. Selective retention of MPP+ within the dopaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience. 40:1991;133-158.
117. Speciale S.G., Liang C.L., Sonsalla P.K., Edwards R.H., German D.C. The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain vesicular monoamine transporter. Neuroscience. 84:1998;1177-1185.
118. Melamed E., Rosenthal J., Cohen O., Globus M., Uzzan A. Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP. Eur J Pharmacol. 116:1985;179-181.
119. Sonsalla P.K., Nicklas W.J., Heikkila R.E. Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science. 243:1989;398-400.
120. Sonsalla P.K., Albers D.S., Zeevalk G.D. Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism. Amino Acids. 14:1998;69-74.
121. Kamisaki Y., Hamahashi T., Hamada T., Maeda K., Itoh T. Presynaptic inhibition by clonidine of neurotransmitter amino acid release in several brain regions. Eur J Pharmacol. 217:1992;57-63.
122. Kamisaki Y., Hamada T., Maeda K., Ishimura M., Itoh T. Presynaptic alpha 2 adrenoceptors inhibit glutamate release from rat spinal cord synaptosomes. J Neurochem. 60:1993;522-526.
123. Fornai F., Alessandrì M.G., Fascetti F., Vaglini F., Corsini G.U. Clonidine suppresses 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced reductions of striatal dopamine and tyrosine hydroxylase activity in mice. J Neurochem. 65:1995;704-709.
124. Albers D.S., Sonsalla P.K. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprorective agents. J Pharmacol Exp Ther. 275:1995;1104-1114.
125. Bowyer J.F., Tank A.W., Newport G.D., Slikker W. Jr., Ali S.F., Holson R.R. The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J Pharmacol Exp Ther. 260:1992;817-824.
126. Leroux-Nicollet I., Panissaud C., Costentin J. Involvement of norepinephrine neurons in the hypothermia induced by intracerebroventricular administration of 6-hydroxydopamine in mice, evidenced by antidepressants. J Neural Transm. 74:1988;17-27.
127. Andén N.-E., Grabowska M. Pharmacological evidence for a stimulation of dopamine neurons by noradrenaline neurons in the brain. Eur J Pharmacol. 39:1976;275-282.
128. Chan P., Di Monte D.A., Luo J.-J., DeLanney L.E., Irwin I., Langston J.W. Rapid ATP loss caused by methamphetamine in the mouse striatum: relationship between energy impairment and dopaminergic neurotoxicity. J Neurochem. 62:1994;2484-2487.
129. Lin R.Z., Chen J., Hu Z.W., Hoffman B.B. Phosphorilation of the cAMP response element-binding protein and activation of transcription by alpha-1 adrenergic receptors. J Biol Chem. 273:1998;30033-30038.
130. Weber G.F. Final common pathways in neurodegenerative diseases: regulatory role of the glutathione cycle. Neurosci Biobehav Rev. 23:1999;1079-1086.
131. Fornai F., Saviozzi M., Piaggi S., Gesi M., Corsini G.U., Malvaldi G., Casini A.F. Localization of a glutathione-dependent dehydroascorbate reductase within the central nervous system of the rat. Neuroscience. 94:1999;937-948.
132. Cirelli C., Tononi G. Changes in gene expression in DSP-4-treated rats revealed by mRNA differential display. Soc Neurosci Abs. 23:1997;689.
133. Fleckenstein A.E., Metzger R.R., Gibb J.W., Hanson G.R. A rapid and reversible change in the dopamine transporters induced by methamphetamine. Eur J Pharmacol. 323:1997;R9-R10.
134. Mason S.T., Fibinger H.C. Regional topography within noradrenergic locus coeruleus as revealed by retrograde transport of horseradish peroxidase. J Comp Neurol. 187:1979;703-724.
135. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol. 46:1999;598-605.
136. Kohutnicka M., Lewandowska E., Kurzowska-Jastrzebska I., Czlonkowski A., Czlonkowska A. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology. 39:1998;167-180.
137. Norris J.G., Benveniste E.N. Interleukin-6 production by astrocytes: induction by the neurotransmitter norepinephrine. J Neuroimmunol. 45:1993;137-145.
138. Kingham P.J., Pocock J.M. Microglial apoptosis induced by chromograinin A is mediated by mitochondrial depolarisation and the permeability transition but not by cytochrom C release. J Neurochem. 74:2000;1452-1462.
139. Antelman S.M., Caggiula A.R. Norepinephrine-dopamine interactions and behavior. Science. 195:1976;646-653.
140. Sonsalla P.K., Nicklas W.J., Heikkila R.E. Role of excitatory amino acids in methamphetamine-induced dopaminergic toxicity. Science. 243:1989;398-400.
141. Fornai F., Vaglini F., Maggio R., Bonuccelli U., Corsini G.U. Species differences in the role of excitatory amino acids in experimental parkinsonism. Neurosci Biobehav Rev. 21:1997;401-415.